Summary and Panel Discussion

Javed Butler; Jonathan Rich; Rachel Pessah-Pollack; John E Anderson

doi:10.1016/j.jchf.2023.11.022

Summary and Panel Discussion

JACC Heart Fail. 2024 Jun;12(6S):S10-S11. doi: 10.1016/j.jchf.2023.11.022.

Authors

Javed Butler¹, Jonathan Rich², Rachel Pessah-Pollack³, John E Anderson⁴

Affiliations

¹ Baylor Scott and White Research Institute, Dallas, Texas, USA; Baylor Scott and White Health, Dallas, Texas, USA; University of Mississippi School of Medicine, Jackson, Mississippi, USA. Electronic address: [email protected].
² Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
³ NYU School of Medicine, New York, New York, USA.
⁴ Frist Clinic, Nashville, Tennessee, USA.

PMID: 38839135
DOI: 10.1016/j.jchf.2023.11.022

Abstract

In this video, Javed Butler, MD, Jonathan Rich, MD, Rachel Pessah-Pollack, MD, and John E. Anderson, MD, summarize the key points of the enhanced publication "Role of SGLT2 Inhibitors in the Management of Heart Failure With and Without Type 2 Diabetes." The panel then delves deeper into some of the topics raised.

Keywords: SGLT2 inhibitors; diagnosis; heart failure; primary care.

Publication types

Video-Audio Media

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Heart Failure* / drug therapy
Humans
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors